Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01974817 · ClinicalTrials.gov registry record · Phase 4
Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease
A Phase 4 study, sponsored by Michigan State University.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT01974817: Completed Phase 4 study, sponsored by Michigan State University.
NCT01974817 is a Phase 4 study that has completed, run by Michigan State University. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01974817, a Phase 4 study, has completed, sponsored by Michigan State University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the response of 13-valent conjugate pneumococcal vaccine in patients 50 years or older with end stage renal disease on dialysis. The study will also try to determine Streptococcus pneumoniae colonization in patients 50 years or older with end stage renal disease on dialysis.
Primary Outcome
Study the immunologic response after administration of single dose 13-valent conjugate pneumococcal vaccine in patients 50 years or older with end stage renal disease on dialysis.
Interventions
- BIOLOGICAL 13-valent conjugate pneumococcal vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 4 |
What the finished NCT01974817 record still lists
NCT01974817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which 13-valent conjugate pneumococcal vaccine is the first listed.
NCT01974817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01974817 about?
NCT01974817 is a clinical study titled "Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease". The purpose of the study is to determine the response of 13-valent conjugate pneumococcal vaccine in patients 50 years or older with end stage renal disease on dialysis. The study will also try to determine Streptococcus pneumoniae colonization in patients 50 years or older with end stage renal dis...
What is the current status of trial NCT01974817?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2013-05. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01974817?
The interventions under investigation include: 13-valent conjugate pneumococcal vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01974817?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01974817's enrollment target sits among peer trials
25 1669th of 2000 higher than 302 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia